文献速递介入腹部US

超声引导经皮微波消融治疗被膜下与非被膜下肝细胞癌的比较

Comparison of ultrasonography-guided percutaneous microwave ablation for subcapsular and nonsubcapsular hepatocellular carcinoma.
PubMed 文献 · Eur J Radiol · 2017-04-05

回顾性比较2012年1月至2015年12月463例单发肝细胞癌患者(被膜下224例、非被膜下239例)行超声引导经皮微波消融的预后;两组技术有效率、累积局部肿瘤进展率、总生存率及主要并发症率均无显著差异,被膜下组术后疼痛率更高(13.4% vs 7.1%,p=0.025)。

要点

  • 被膜下与非被膜下肝细胞癌微波消融后技术有效率、局部进展率、总生存率及主要并发症率均无显著差异。
  • 被膜下组术后疼痛发生率13.4%,高于非被膜下组7.1%(p=0.025)。
  • 被膜下位置并非微波消融疗效或主要并发症的显著影响因素。

核心结论

  • 超声引导经皮微波消融治疗被膜下与非被膜下肝细胞癌在技术有效率、累积局部肿瘤进展率、总生存率和主要并发症率上无显著差异。

研究设计与样本

  • 2012年1月至2015年12月纳入463例单发肝细胞癌患者(男382例、女81例,年龄24-95岁),按肿瘤位置分为被膜下组224例和非被膜下组239例,均行超声引导经皮微波消融,术后以增强影像评估疗效。

诊断标准与关键数值

  • 技术有效率:被膜下组95.5% vs 非被膜下组98.3%,p=0.089,无显著差异。
  • 1、2、3、4年累积局部肿瘤进展率:被膜下组分别为5.0%、5.5%、5.5%、5.5%,非被膜下组分别为6.4%、6.4%、6.4%、6.4%,p=0.861。
  • 1、2、3、4年总生存率:被膜下组分别为95.7%、90.1%、82.9%、71.1%,非被膜下组分别为98.5%、92.8%、83.2%、73.6%,p=0.426。
  • 主要并发症率:被膜下组2.2% vs 非被膜下组1.3%,p=0.653,无显著差异。
  • 术后疼痛率:被膜下组13.4% vs 非被膜下组7.1%,p=0.025,被膜下组更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To compare the prognosis of subcapsular and nonsubcapsular hepatocellular carcinoma (HCC) after ultrasonography (US)-guided percutaneous microwave ablation (MWA).

MATERIALS AND METHODS: From January 2012 to December 2015, 463 enrollment patients (382 men, 81 women; age range, 24-95 years) with a single HCC underwent US-guided percutaneous MWA. The patients were divided into two groups according to tumor location: subcapsular (n=224) and nonsubcapsular (n=239). Therapeutic efficacy was assessed by contrast enhanced imaging after MWA. The technique effectiveness rate, the local tumor progression (LTP) rate, overall survival (OS) rate and complication were compared between two groups.

RESULTS: There were no significant differences in the mean treatment sessions (p=0.105) and the mean number of antenna insertions (p=0.065) between two groups. No significant difference in the technique effectiveness rate was found between subcapsular and nonsubcapsular tumors (95.5% vs 98.3%, p=0.089). The respective 1-, 2-, 3-, and 4-year cumulative LTP rates were 5.0%, 5.5%, 5.5% and 5.5% in subcapsular group and 6.4%, 6.4%, 6.4% and 6.4% in nonsubcapsular group, respectively(p=0.861). The 1-, 2-, 3-, and 4-year OS rates were estimated to be 95.7%, 90.1%, 82.9%, and 71.1% in subcapsular group and 98.5%, 92.8%, 83.2%, and 73.6% in nonsubcapsular group, respectively (p=0.426). There was no significant difference in major complication rates between the subcapsular group (2.2%) and nonsubcapsular group (1.3%) (p=0.653). There was higher postoperative pain rate in subcapsular group (13.4%) than nonsubcapsular group (7.1%) (p=0.025).

CONCLUSIONS: There were no significant differences in the technique effectiveness rate, cumulative LTP rate, OS rate and major complication rate between subcapsular and nonsubcapsular group after MWA for HCC.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Liu F, Yu X, Cheng Z, et al. Comparison of ultrasonography-guided percutaneous microwave ablation for subcapsular and nonsubcapsular hepatocellular carcinoma. Eur J Radiol. 2017. PMID: 28629577. doi:10.1016/j.ejrad.2017.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。